Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Teva Coreg Damages Reinstated As AAM Bemoans ‘Antithetical’ Ruling
Israeli Firm Is On Hook Again For $235m Payment
Oct 07 2020
•
By
Dean Rudge
Teva is facing the prospect of nearly a quarter of a billion of dollars of damages once again • Source: Shutterstock
More from Legal & IP
More from Generics Bulletin